BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Citi initiates Dr. Lal Pathlabs with buy
Company is a multi-year growth play. High return ratio will drive higher earnings multiples. See potentially higher dividends in the company. See a 50 per cent premium to average Asian hospitals.